Bioprofiling and vaccine development for Zika virus

Huiping Shi; Shengyong Feng; Abid Naeem; Baoying Huang; Wenjie Tan; Lulu Zheng; Xing-Jie Liang; Minghui Yang; Yuanyu Huang

doi:10.1007/s11427-024-2851-4

Bioprofiling and vaccine development for Zika virus

Sci China Life Sci. 2025 Jun 3. doi: 10.1007/s11427-024-2851-4. Online ahead of print.

Authors

Huiping Shi¹, Shengyong Feng², Abid Naeem¹, Baoying Huang³, Wenjie Tan³, Lulu Zheng¹, Xing-Jie Liang⁴, Minghui Yang^{5

6}, Yuanyu Huang^{7

8}

Affiliations

¹ School of Life Science, Advanced Research Institute of Multidisciplinary Science, Aerospace Center Hospital, School of Medical Technology, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing, 100081, China.
² School of Basic Medical Sciences, Tsinghua University, Beijing, 100084, China.
³ National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Key Laboratory of Biosafety, National Health Commissions, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
⁴ CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, 100190, China.
⁵ School of Life Science, Advanced Research Institute of Multidisciplinary Science, Aerospace Center Hospital, School of Medical Technology, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing, 100081, China. yangmh17@bit.edu.cn.
⁶ Advanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology (BIT), Zhuhai, 519088, China. yangmh17@bit.edu.cn.
⁷ School of Life Science, Advanced Research Institute of Multidisciplinary Science, Aerospace Center Hospital, School of Medical Technology, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing, 100081, China. yyhuang@bit.edu.cn.
⁸ Advanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology (BIT), Zhuhai, 519088, China. yyhuang@bit.edu.cn.

PMID: 40471494
DOI: 10.1007/s11427-024-2851-4

Abstract

Zika virus (ZIKV) has emerged as a global health priority due to its association with severe congenital abnormalities, including microcephaly and neonatal mortality in infants born to infected mothers. In adults, ZIKV infection is epidemiologically linked to Guillain-Barré Syndrome (GBS). These clinical manifestations prompted the World Health Organization (WHO) to declare ZIKV a Public Health Emergency of International Concern (PHEIC). The antibody-dependent enhancement (ADE) phenomenon further complicates vaccine development and therapeutic strategies. While substantial progress has been made in elucidating ZIKV biology through multidisciplinary approaches, no vaccines or therapies have been clinically approved. This review examines ZIKV-associated risks by analyzing transmission dynamics, viral architecture, and cellular entry mechanisms, and proposes evidence-based prevention and management strategies.

Keywords: Zika virus; invasion mechanisms; transmission pathways; vaccines; viral structure.

Publication types

Review